The tweet was deleted by the author.
But we saved everything 🙂.
Caribou Biosciences announced it will discontinue its allogeneic CAR-T cell therapy programs due to difficulties in securing the necessary funding to advance these initiatives.
The company stated it is evaluating strategic alternatives as it faces ongoing challenges accessing capital required for further development.
View post on X Loading...
Caribou Biosciences was previously named a finalist for Citeline's 2026 Best Oncology R and D Advance Award for its vispa-cel therapy, according to a recent report. The company had highlighted vispa-cel as a key asset in its pipeline. The latest decision to halt allogeneic CAR-T programs follows ongoing challenges in funding these developments.